Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Agrees To Pay $500 Million To Resolve Manufacturing Violations At Indian Sites

This article was originally published in PharmAsia News

Executive Summary

In the final stage of a drawn-out saga, Ranbaxy will pay $500 million to U.S. federal agencies to settle civil and criminal proceedings related to manufacture and supply of adulterated drugs from two Indian sites.

Advertisement

Related Content

Ranbaxy’s $500 Million GMP Settlement Would Be Second Most Expensive For Rx Manufacturing Violations
Ranbaxy Woes Continue With 30-plus Product Import Alert

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC084271

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel